Health Affairs February 21, 2025
Respiratory syncytial virus (RSV) is a cold-like illness that can be dangerous for infants, especially those born during the respiratory season. We finally have a tool to protect them, yet entrenched reimbursement models may stand in the way, disincentivizing providers in hospital labor and delivery units from offering it.
Nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity against RSV in infants and young children. The Advisory Committee on Immunization Practices (ACIP) recommends routine administration of nirsevimab for infants under 8 months born during the RSV season (September to March), depending on the mother’s RSV vaccination status.
Importantly, ACIP recommends that nirsevimab be administered within one week of birth, either during the birth hospitalization or in an outpatient...
Today's Sponsors
Today's Sponsor